Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 415 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo medication + placebo alcohol Clear all
Recruiting Phase 4 Interventional Accepts healthy volunteers

Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder

NCT06426303
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone
Drug
Lead sponsor
Milky Kohno
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 4, 2026, 2:36 AM EDT
Completed Phase 4 Interventional Results available

Rib Fracture Analgesia Using Cryoanalgesia

NCT04198662
View directory record Official record
Conditions
Traumatic Rib Fracture(s)
Interventions
Cryoneurolysis with a Painblocker (Epimed International, Farmers Branch, Texas), Intercostal nerve block ropivacaine with epinephrine, Sham cryoneurolysis with a Painblocker, Placebo intercostal nerve block with normal saline
Device · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 4, 2026, 2:36 AM EDT
Terminated Phase 3 Interventional

Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction

NCT00634829
View directory record Official record
Conditions
Asthma, Bronchospasm
Interventions
albuterol (Armstrong Albuterol HFA), Albuterol Sulfate (Provenetil-HFA), Placebo-HFA
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Denver, Colorado • Englewood, Colorado • Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 4, 2026, 2:36 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478696
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
42
States / cities
Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 4, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma

NCT00746330
View directory record Official record
Conditions
Asthma
Interventions
Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF
Drug
Lead sponsor
Novartis
Industry
Eligibility
5 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Mobile, Alabama • Huntington Beach, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Oct 4, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

Harm Reduction With Pharmacotherapy (HaRP)

NCT01932801
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
XR-NTX, Placebo, HRC
Drug · Other · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 65 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 4, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

Modafinil for the Treatment of Alcohol Use Disorders

NCT03424681
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Modafinil, Placebo
Drug · Other
Lead sponsor
The Mind Research Network
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 4, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

A Novel Human Lab Model for Screening AUD Medications

NCT04249882
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Placebo, Naltrexone, Varenicline
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 4, 2026, 2:36 AM EDT
Recruiting Early Phase 1 Interventional

Propranolol in Primary Progressive Aphasia

NCT06066710
View directory record Official record
Conditions
Aphasia, Primary Progressive
Interventions
Propranolol, Magnetic Resonance Imaging (MRI), Placebo
Drug · Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 4, 2026, 2:36 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Alcohol Dependence and Comorbid Bipolar Disorder

NCT01015586
View directory record Official record
Conditions
Alcohol Dependence, Bipolar Disorder, Depression, Mania, Psychosis
Interventions
Lamotrigine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 4, 2026, 2:36 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02141854
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, Albuterol/salmeterol HFA MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
85
States / cities
Birmingham, Alabama • Little Rock, Alaska • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 4, 2026, 2:36 AM EDT
Recruiting Phase 2 Interventional

Suvorexant for Treatment of AUD and PTSD

NCT06679062
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD), Insomnia
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Other
Eligibility
21 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 4, 2026, 2:36 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

NCT07810946
View directory record Official record
Conditions
Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions
Sodium Acetate, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 4, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain

NCT07053774
View directory record Official record
Conditions
Pain, Acute
Interventions
Intravenous oxytocin, Intravenous placebo, Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 4, 2026, 2:36 AM EDT
Active, not recruiting Phase 2 Interventional

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

NCT04620759
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 4, 2026, 2:36 AM EDT
Completed Phase 4 Interventional Results available

Drug and Non-Drug Treatment Of Severe Migraine

NCT00910689
View directory record Official record
Conditions
Migraine Headache
Interventions
Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy
Drug · Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 65 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Athens, Ohio • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 4, 2026, 2:36 AM EDT
Completed Phase 3 Interventional

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

NCT01508026
View directory record Official record
Conditions
Stage 1 Hypertension, Stage 2 Hypertension
Interventions
Nebivolol and Valsartan 1, Nebivolol and Valsartan 2, Nebivolol and Valsartan 3, Nebivolol 1, Nebivolol 2, Valsartan 1, Valsartan 2, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
4,161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
413
States / cities
Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 290 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 4, 2026, 2:36 AM EDT
Enrolling by invitation Phase 2 Interventional

Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

NCT05285878
View directory record Official record
Conditions
Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection, Kidney Transplant Failure, Kidney Failure, Chronic, Graft Rejection
Interventions
Fingolimod, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 4, 2026, 2:36 AM EDT
Completed Phase 4 Interventional Results available

Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems

NCT02504931
View directory record Official record
Conditions
PTSD, Alcohol Use Disorder
Interventions
Sertraline, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 4, 2026, 2:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence

NCT02120365
View directory record Official record
Conditions
Alcoholism
Interventions
Perampanel, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Farmington, Connecticut • New Haven, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 4, 2026, 2:36 AM EDT
Active, not recruiting Early Phase 1 Interventional

Modafinil and Cognitive Function in POTS

NCT01988883
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Placebo, Modafinil, Propranolol
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 4, 2026, 2:36 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Safety of Twice Daily Oral Carvedilol

NCT00129363
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Carvedilol
Drug
Lead sponsor
Shaddy, Robert, M.D.
Individual
Eligibility
1 Day to 17 Years
Enrollment
75 participants
Timeline
2002 – 2006
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2008 · Synced Oct 4, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving

NCT01822587
View directory record Official record
Conditions
Cocaine Addiction
Interventions
Propranolol, 40 mg, Propranolol, 80 mg, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 4, 2026, 2:36 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

NCT06643221
View directory record Official record
Conditions
Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion, CAR T-Cell Therapy, Lymphoma, Cell Therapy
Interventions
Exercise, Isoproterenol, Placebo, Bisoprolol Fumarate Tablet 10 mg, Nadolol (1 x 80 mg) Tablets (Invamed, Inc), Carvedilol 50 mg, Roflumilast 500 Mcg Oral Tablet
Behavioral · Drug
Lead sponsor
University of Arizona
Other
Eligibility
21 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2031
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 4, 2026, 2:36 AM EDT